Le Gall, T.; Berchel, M.; Davies, L.; Mottais, A.; Ghanem, R.; Fautrel, A.; Gill, D.; Hyde, S.; Lehn, P.; Lehn, J.-M.;
et al. Aerosol-Mediated Non-Viral Lung Gene Therapy: The Potential of Aminoglycoside-Based Cationic Liposomes. Pharmaceutics 2022, 14, 25.
https://doi.org/10.3390/pharmaceutics14010025
AMA Style
Le Gall T, Berchel M, Davies L, Mottais A, Ghanem R, Fautrel A, Gill D, Hyde S, Lehn P, Lehn J-M,
et al. Aerosol-Mediated Non-Viral Lung Gene Therapy: The Potential of Aminoglycoside-Based Cationic Liposomes. Pharmaceutics. 2022; 14(1):25.
https://doi.org/10.3390/pharmaceutics14010025
Chicago/Turabian Style
Le Gall, Tony, Mathieu Berchel, Lee Davies, Angélique Mottais, Rosy Ghanem, Alain Fautrel, Deborah Gill, Steve Hyde, Pierre Lehn, Jean-Marie Lehn,
and et al. 2022. "Aerosol-Mediated Non-Viral Lung Gene Therapy: The Potential of Aminoglycoside-Based Cationic Liposomes" Pharmaceutics 14, no. 1: 25.
https://doi.org/10.3390/pharmaceutics14010025
APA Style
Le Gall, T., Berchel, M., Davies, L., Mottais, A., Ghanem, R., Fautrel, A., Gill, D., Hyde, S., Lehn, P., Lehn, J. -M., Lemiègre, L., Benvegnu, T., Jaffrès, P. -A., Pitard, B., & Montier, T.
(2022). Aerosol-Mediated Non-Viral Lung Gene Therapy: The Potential of Aminoglycoside-Based Cationic Liposomes. Pharmaceutics, 14(1), 25.
https://doi.org/10.3390/pharmaceutics14010025